ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferences:

  • Jefferies London Healthcare Conference. Dr. Neal Walker, the President and CEO of Aclaris, will participate in a virtual fireside chat which will be available beginning on Thursday, November 18, 2021 at 3:00 a.m. ET. Management will be available November 18th throughout the day for virtual one-on-one meetings.



  • Piper Sandler 33rd Annual Virtual Healthcare Conference. Dr. Walker will participate in a virtual fireside chat which will be available beginning on Monday, November 22, 2021 at 10:00 a.m. ET. Management will be available December 1st throughout the day for virtual one-on-one meetings.

A live webcast of each fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, Each webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit

Aclaris Contact



EN
03/11/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aclaris Therapeutics Inc.

 PRESS RELEASE

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and ...

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of Phase 2 Trial in an Additional Indication Expected in the First Half of 2026 - - Timelines Reiterated for Top Line Clinical Results from Ongoing Trials of Investigational Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) and Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Initiatio...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Aclaris Therapeutics to Participate in Three November Healthcare Confe...

Aclaris Therapeutics to Participate in Three November Healthcare Conferences WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November. On Wednesday November 12, 2025, at 11:00 AM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Gu...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

ResearchPool Subscriptions

Get the most out of your insights

Get in touch